Breaking News Instant updates and real-time market news.

BIO

Bio-Rad

$308.27

-7.12 (-2.26%)

16:50
08/07/18
08/07
16:50
08/07/18
16:50

Bio-Rad reports Q2 adjusted EPS $1.64, consensus $1.27

Reports Q2 revenue $575.9M, consensus $548.43M.

  • 07

    Aug

BIO Bio-Rad
$308.27

-7.12 (-2.26%)

02/22/18
JEFF
02/22/18
NO CHANGE
Target $300
JEFF
Buy
Jefferies sees low valuation and expectations into Bio-Rad's Q4 print
Jefferies analyst Brandon Couillard says Bio-Rad Laboratories' valuation is low and expectations appear low while the company's fundamentals are improving. He thinks the street has overlooked the recovery in Sartorius, which he notes has added $800M of value year-to-date for the company. Couillard has a positive bias into the Q4 print and sees a "clear path to margin expansion upside" in 2018. He keeps a Buy rating on Bio-Rad with a $300 price target.
02/28/18
DBAB
02/28/18
NO CHANGE
Target $325
DBAB
Buy
Bio-Rad price target raised to $325 from $309 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Bio-Rad Laboratories to $325 citing the better than expected Q4 results. The analyst says the company's guidance for even better margin improvement in 2018 supports his Buy thesis.
02/28/18
JEFF
02/28/18
NO CHANGE
Target $325
JEFF
Buy
Bio-Rad price target raised to $325 from $300 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Bio-Rad Laboratories to $325 saying the second half of 2017 margin ramp and initial 2018 outlook "should quell debate" over the company's ability to execute and the relevancy of its 2020 goals. Couillard says Bio-Rad remains his top pick and the "most compelling absolute value we can find." He keeps a Buy rating on the shares following the company's Q4 results.
03/20/18
WELS
03/20/18
NO CHANGE
Target $290
WELS
Outperform
Bio-Rad price target raised to $290 from $280 at Wells Fargo
Wells Fargo analyst Tim Evans raised his price target for Bio-Rad to $290 from $280 to reflect an increase in the value of the company's stake in Sartorius. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.